Last reviewed · How we verify

Gynuity Health Projects — Portfolio Competitive Intelligence Brief

Gynuity Health Projects pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Buccal misoprostol Buccal misoprostol marketed
Mifepristone + Misoprostol Mifepristone + Misoprostol marketed Progesterone receptor antagonist + prostaglandin analog combination Progesterone receptor (PR); prostaglandin E1 receptor (EP receptor) Reproductive Health / Gynecology
Mifepristone and misoprostol Mifepristone and misoprostol marketed Progesterone antagonist + prostaglandin analog combination Progesterone receptor (mifepristone); prostaglandin E1 receptor (misoprostol) Reproductive Health / Obstetrics
Placebo mifepristone Placebo mifepristone marketed

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hadassah Medical Organization · 1 shared drug class
  2. Planned Parenthood League of Massachusetts · 1 shared drug class
  3. Reproductive Health Training Center of the Republic of Moldova · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gynuity Health Projects:

Cite this brief

Drug Landscape (2026). Gynuity Health Projects — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gynuity-health-projects. Accessed 2026-06-10.

Related